286 related articles for article (PubMed ID: 30216694)
1. Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma.
Almeida FV; Douglass SM; Fane ME; Weeraratna AT
Pigment Cell Melanoma Res; 2019 Mar; 32(2):237-247. PubMed ID: 30216694
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma.
Mourah S; Louveau B; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):91-97. PubMed ID: 31833956
[TBL] [Abstract][Full Text] [Related]
3. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
[TBL] [Abstract][Full Text] [Related]
4. AMBRA1 levels predict resistance to MAPK inhibitors in melanoma.
Di Leo L; Pagliuca C; Kishk A; Rizza S; Tsiavou C; Pecorari C; Dahl C; Pacheco MP; Tholstrup R; Brewer JR; Berico P; Hernando E; Cecconi F; Ballotti R; Bertolotto C; Filomeni G; Gjerstorff MF; Sauter T; Lovat P; Guldberg P; De Zio D
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2400566121. PubMed ID: 38870061
[TBL] [Abstract][Full Text] [Related]
5. Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival.
Afasizheva A; Devine A; Tillman H; Fung KL; Vieira WD; Blehm BH; Kotobuki Y; Busby B; Chen EI; Tanner K
BMC Cancer; 2016 Mar; 16():186. PubMed ID: 26944546
[TBL] [Abstract][Full Text] [Related]
6. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
10. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era.
Wattson DA; Sullivan RJ; Niemierko A; Merritt RM; Lawrence DP; Oh KS; Flaherty KT; Shih HA
J Neurooncol; 2015 May; 123(1):75-84. PubMed ID: 25864098
[TBL] [Abstract][Full Text] [Related]
11. Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.
Hong A; Moriceau G; Sun L; Lomeli S; Piva M; Damoiseaux R; Holmen SL; Sharpless NE; Hugo W; Lo RS
Cancer Discov; 2018 Jan; 8(1):74-93. PubMed ID: 28923912
[TBL] [Abstract][Full Text] [Related]
12. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
13. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
Mandalà M; Massi D
Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
[TBL] [Abstract][Full Text] [Related]
14. Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.
Song C; Piva M; Sun L; Hong A; Moriceau G; Kong X; Zhang H; Lomeli S; Qian J; Yu CC; Damoiseaux R; Kelley MC; Dahlman KB; Scumpia PO; Sosman JA; Johnson DB; Ribas A; Hugo W; Lo RS
Cancer Discov; 2017 Nov; 7(11):1248-1265. PubMed ID: 28864476
[TBL] [Abstract][Full Text] [Related]
15. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
Zhang G; Frederick DT; Wu L; Wei Z; Krepler C; Srinivasan S; Chae YC; Xu X; Choi H; Dimwamwa E; Ope O; Shannan B; Basu D; Zhang D; Guha M; Xiao M; Randell S; Sproesser K; Xu W; Liu J; Karakousis GC; Schuchter LM; Gangadhar TC; Amaravadi RK; Gu M; Xu C; Ghosh A; Xu W; Tian T; Zhang J; Zha S; Liu Q; Brafford P; Weeraratna A; Davies MA; Wargo JA; Avadhani NG; Lu Y; Mills GB; Altieri DC; Flaherty KT; Herlyn M
J Clin Invest; 2016 May; 126(5):1834-56. PubMed ID: 27043285
[TBL] [Abstract][Full Text] [Related]
16. Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance.
Singh MK; Altameemi S; Lares M; Newton MA; Setaluri V
Sci Rep; 2022 Aug; 12(1):14395. PubMed ID: 35999349
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
18. In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.
Madorsky Rowdo FP; Barón A; von Euw EM; Mordoh J
Oncol Rep; 2017 Mar; 37(3):1367-1378. PubMed ID: 28098866
[TBL] [Abstract][Full Text] [Related]
19. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
20. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
Capovilla M
Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]